Bellicum Pharmaceuticals (BLCM) Key Ratios

$0.07

up-down-arrow $-0.13 (-62.65%)

As on 04-Mar-2024 14:59EDT

Market cap

info icon

$1 Mln

Revenue (TTM)

info icon

$2 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

40.3

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- 0.00 0.53 -47.24 15.33
EBIT 99.96 99.96 7.99 14.10 11.76
Net Profit 89.62 89.49 -41.72 17.13 12.03
EPS 89.65 89.52 -275.60 22.91 14.13
Book Value -- -- -77.32 -- -57.52
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-22Dec-21
EBIT-Margin info -4,179.40-4,457.00-1,509.75-1,798.73-401.06
Net Margin info -18.29-887.83-1,445.42----
Return on equity info -72.19-188.27---189.12-87.48
Return on Capital info -145.50-148.17---189.12-83.05
Return on Assets info -33.60-56.63-94.50-68.45-21.35
Debt to Equity (x) info ----0.00----
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
--
-189.12
-83.05
-164.33
-216.92
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

--

--

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
--
-189.12
-87.48
60.03
-596.73
Peer Median
-40.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-94.50

Lower than Peers by 63.25

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
-94.50
-68.45
-21.35
-10.99
-106.07
Peer Median
-31.24
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-1,509.75

Lower than Peers by 1,427.15

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
-1,509.75
-1,798.73
-401.06
-10,338.40
-1,223.07
Peer Median
-82.60
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-1,445.42

Lower than Peers by 1,354.13

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
-1,445.42
-1,664.87
-154.48
-18.29
921.05
Peer Median
-91.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

-0.16

Lower than Peers by 0.16

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
-0.16
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

0.53

Lower than Peers by 53.50

Year on year growth in net sales

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
0.53
-0.76
11.40
-0.93
5.38
Peer Median
54.03
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

7.99

Higher than Peers by 9.01

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
7.99
-8.51
51.90
40.83
8.49
Peer Median
-1.02
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-41.72

Lower than Peers by 34.19

Year on year growth in profit after tax

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
-41.72
-160.73
-11.13
93.16
-28.62
Peer Median
-7.53
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-275.60

Lower than Peers by 289.83

Year on year growth in earnings per share

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
-275.60
-6.16
0.44
0.96
-0.12
Peer Median
14.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-459.38

Lower than Peers by 449.24

Year on year growth in book value per share

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
-459.38
--
--
--
--
Peer Median
-10.13
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
--
--
--
-0.47
-1.45
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
--
--
--
-0.33
-0.44
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

3.04

Lower than Peers by 2.77

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
3.04
6.31
7.32
1.60
1.18
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

3.04

Lower than Peers by 2.65

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
3.04
6.36
7.10
1.47
0.98
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-36.93

Lower than Peers by 34.84

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
-36.93
-586,543.48
-6,216.50
-19.44
-20.41
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

0.99

Lower than Peers by 18.02

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
0.99
13.67
3.31
0.40
4.24
Peer Median
19.01
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.07

Higher than Peers by 0.00

Sales / Average Total Assets

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
0.07
0.04
0.14
0.01
0.06
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
--
49.92
6.10
111.40
66.45
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
--
--
--
--
53.36
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
--
--
--
--
18.76
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
--
--
--
--
101.05
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
--
-0.17
-2.46
-3.25
-0.05
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

40.34

Higher than Peers by 35.01

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
40.34
2.06
0.97
-11.22
-0.25
Peer Median
5.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

1.91

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
1.91
0.61
0.93
0.12
0.68
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

1

Lower than Peers by 141

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Bellicum Pharmaceuticals (BLCM)
1
--
--
--
--
Peer Median
142
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...